<DOC>
	<DOCNO>NCT02442960</DOCNO>
	<brief_summary>This 12-week , open-label , dose-escalation Phase 1b study herbal treatment give orally subject ulcerative colitis . Subjects sequentially enrol one two cohort two clinical site . Treatment give 8 week study duration 12 week .</brief_summary>
	<brief_title>Evaluating Safety Efficacy Herbal Treatment Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>1 . Age ≥ 18 year ≤ 75 year . 2 . Mildtomoderate ulcerative colitis ( biopsyproven ) . 3 . Mayo Scoring System Assessment Ulcerative Colitis Activity score 3 10 screening . 4 . Patients active disease refractory , intolerant , unwilling take 5aminosalicylic acid ( 5ASA ) . 5 . Physician 's Global Assessment ( PGA ) Mayo subscore least 1 screen . 6 . Mayo rectal bleeding subscore least 1 screen . 7 . Endoscopic evidence active mucosal disease assess flexible sigmoidoscopy Mayo mucosal appearance subscore least 1 screen . 8 . Female patient childbearing potential must negative serum pregnancy test screen visit agree use two medically reliable method contraception ( barrier either spermicide hormonal contraception ) study period . 9 . Male patient must willing use acceptable contraceptive method assure female partner childbearing potential use acceptable contraceptive method study period . 10 . Ability adhere study visit schedule protocol requirement . 11 . Adequate cardiac , renal , hepatic function determine principal investigator . 12 . Written inform consent obtain study procedure perform . 1 . Are nurse pregnant . 2 . Patients critical condition 3 . Crohn 's disease indeterminate colitis . 4 . Known sensitivity ingredient study drug . 5 . A change therapy within 2 week baseline visit . 6 . Use immunomodulators ( cyclosporine , mercaptopurine , azathioprine , etc. ) . 7 . Diagnosis diabetes , heart failure , unstable angina , liver kidney disease , unstable medical condition . 8 . Any clinically meaningful laboratory abnormality judgment investigator preclude participation study . 9 . Impaired renal function ( serum creatinine level &gt; 2.0 mg/dL ) screening . 10 . Alanine transaminase ( ALT ) aspartate transaminase ( AST ) laboratory value &gt; 1.5 time upper limit normal screening . 11 . Diagnosis Clostridium difficile , Salmonella , Shigella , Yersinia , Campylobacter , enteropathogenic E. coli stool . 12 . Positive test hepatitis C virus ( HCV ) antibody hepatitis B surface antigen ( HBsAg ) screening . 13 . Active malignancy ( except basal cell carcinoma ) . 14 . Active alcohol drug abuse . 15 . Tobacco smoking within 2 week study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>